Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 2,994 |
|
|||||
| News | - | ||||||
| Day High | 25.00 | Low High |
|||||
| Day Low | 23.93 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| vTv Therapeutics Inc | VTVT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.395 | 1.64% | 24.435 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 24.00 | 23.93 | 25.00 | 24.435 | 24.04 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 266 | 2,994 | $ 24.43 | $ 73,149 | - | 7.38 - 39.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 21 | $ 24.21 | USD |
vTv Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 73.55M | - | - | - | -383.68 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
vTv Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTVT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 24.74 | 25.00 | 23.00 | 24.45 | 7,759 | -0.305 | -1.23% |
| 1 Month | 21.22 | 26.5399 | 19.1203 | 24.02 | 9,351 | 3.22 | 15.15% |
| 3 Months | 8.19 | 30.99 | 7.8001 | 16.87 | 73,737 | 16.25 | 198.35% |
| 6 Months | 17.24 | 30.99 | 7.38 | 15.21 | 63,319 | 7.20 | 41.73% |
| 1 Year | 30.40 | 39.60 | 7.38 | 24.64 | 111,109 | -5.97 | -19.62% |
| 3 Years | 94.00 | 115.20 | 7.38 | 62.53 | 480,629 | -69.57 | -74.01% |
| 5 Years | 51.60 | 205.20 | 7.38 | 97.44 | 954,661 | -27.17 | -52.65% |
vTv Therapeutics Description
| vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. |
